Marinus Pharmaceuticals traded at $8.38 this Tuesday April 9th, increasing $0.18 or 2.20 percent since the previous trading session. Looking back, over the last four weeks, Marinus Pharmaceuticals gained 1.18 percent. Over the last 12 months, its price rose by 19.37 percent. Looking ahead, we forecast Marinus Pharmaceuticals to be priced at 8.20 by the end of this quarter and at 7.69 in one year, according to Trading Economics global macro models projections and analysts expectations.
Marinus Pharmaceuticals Inc is a United States-based biopharmaceutical company. The Company offers development and commercialization of medical drugs for the treatment of serious neurological and psychiatric disorders such as epilepsy, post-traumatic stress, and fragile-x syndrome. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.